Cantitate/Preț
Produs
Total produse
Vezi coșul
Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer de Michail Ignatiadis

Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer: Recent Results in Cancer Research, cartea 195

Editat de Michail Ignatiadis, Christos Sotiriou, Klaus Pantel
en Limba Engleză Hardback – 23 apr 2012
This important book provides up-to-date information on a series of topical issues relating to the approach to minimal residual disease in breast cancer patients. It first explains how the study of minimal residual disease and circulating and disseminated tumor cells (CTCs/DTCs) can assist in the understanding of breast cancer metastasis. A series of chapters then discuss the various technologies available for the detection and characterization of CTCs and DTCs, pinpointing their merits and limitations. Detailed consideration is given to the relevance of CTCs and DTCs, and their detection, to clinical research and practice. The role of other blood-based biomarkers is also addressed, and the closing chapters debate the challenges facing drug and biomarker co-development and the use of CTCs for companion diagnostic development. This book will be of interest and assistance to all who are engaged in the modern management of breast cancer.
Citește tot Restrânge

Toate formatele și edițiile

Toate formatele și edițiile Preț Express
Paperback (1) 77755 lei  6-8 săpt.
  Springer Berlin, Heidelberg – 9 mai 2014 77755 lei  6-8 săpt.
Hardback (1) 109848 lei  6-8 săpt.
  Springer Berlin, Heidelberg – 23 apr 2012 109848 lei  6-8 săpt.

Din seria Recent Results in Cancer Research

  • 5% Cancer Clinical Trials: A Critical Appraisal
    Preț: 30177 lei
  • 5% Regulatory and Economic Aspects in Oncology
    Preț: 84519 lei
  • 5% Tumor Liquid Biopsies
    Preț: 19169 lei
  • 5% Viruses and Human Cancer: From Basic Science to Clinical Prevention
    Preț: 78246 lei
  • 5% Ethical Challenges in Cancer Diagnosis and Therapy
    Preț: 91376 lei
  • 5% Liver Fluke, Opisthorchis viverrini Related Cholangiocarcinoma: Liver Fluke Related Cholangiocarcinoma
    Preț: 91923 lei
  • 5% Current Problems in the Epidemiology of Cancer and Lymphomas: Symposium of the Gesellschaft zur Bekämpfung der Krebskrankheiten, Nordrhein-Westfalen, e. V
    Preț: 40028 lei
  • 15% Die tierische Zelle in Zellkultur
    Preț: 49042 lei
  • 5% Radioactive Phosphorus in the Diagnosis of Gastrointestinal Cancer
    Preț: 70383 lei
  • 5% Therapeutic Strategies in Primary and Metastatic Liver Cancer
    Preț: 72105 lei
  • 5% Locoregional High-Frequency Hyperthermia and Temperature Measurement
    Preț: 70935 lei
  • 5% Epidemiology of Malignant Melanoma
    Preț: 71115 lei
  • 5% Preoperative (Neoadjuvant) Chemotherapy
    Preț: 71060 lei
  • 5% Hyperthermia and the Therapy of Malignant Tumors
    Preț: 71333 lei
  • 5% Breast Cancer: Present Perspective of Early Diagnosis
    Preț: 36180 lei
  • 5% Minimal Neoplasia: Diagnosis and Therapy
    Preț: 71260 lei
  • 5% Application of Hyperthermia in the Treatment of Cancer
    Preț: 37110 lei
  • 5% Supportive Care in Cancer Patients
    Preț: 72196 lei
  • 5% Preclinical Hyperthermia
    Preț: 71684 lei
  • 5% Treatment of Skin Cancer
    Preț: 35632 lei
  • 5% Combined Modality Therapy of Gastrointestinal Tract Cancer
    Preț: 71974 lei
  • 5% AIDS-Related Neoplasias
    Preț: 35960 lei
  • 5% Endocrine Therapy and Growth Regulation of Breast Cancer
    Preț: 70641 lei
  • 5% Cancer Mapping
    Preț: 71773 lei
  • 5% Adjuvant Therapy of Primary Breast Cancer
    Preț: 71919 lei
  • 5% Bisphosphonates and Tumor Osteolysis
    Preț: 70532 lei
  • 5% New Aspects in the Diagnosis and Treatment of Hodgkin’s Disease: First International Symposium on Hodgkin's Lymphoma in Cologne, October 2-3, 1987
    Preț: 71829 lei
  • 5% Hormone-Related Malignant Tumors
    Preț: 71720 lei
  • 5% Advances in Breast Cancer Detection
    Preț: 71115 lei
  • 5% Hereditary Factors in Carcinoma
    Preț: 71225 lei
  • 5% Occupational Cancer Epidemiology
    Preț: 71096 lei
  • 5% Supportive Care in Cancer Patients II
    Preț: 37897 lei
  • 5% Pathobiology of Human Germ Cell Neoplasia
    Preț: 108968 lei
  • 5% Peptides in Oncology I: LH-RH Agonists and Antagonists
    Preț: 36106 lei
  • 5% Medullary Thyroid Carcinoma
    Preț: 71225 lei
  • 5% Malignancies of the Genitourinary Tract
    Preț: 71555 lei
  • 5% Adjuvant Therapy of Breast Cancer IV
    Preț: 71684 lei
  • 5% Skin Carcinogenesis in Man and in Experimental Models
    Preț: 72068 lei
  • 5% Peptides in Oncology II: Somatostatin Analogues and Bombesin Antagonists
    Preț: 70786 lei
  • 5% Tumours in Children
    Preț: 73201 lei
  • 5% Acute and Long-Term Side-Effects of Radiotherapy: Biological Basis and Clinical Relevance
    Preț: 71591 lei
  • 5% Recent Advances in Cell Biology of Acute Leukemia: Impact on Clinical Diagnosis and Therapy
    Preț: 72305 lei
  • 5% Infectious Complications in Bone Marrow Transplantation
    Preț: 36910 lei
  • 5% Current Status of Diagnostic Cytology
    Preț: 70935 lei
  • 5% Carcinoma of the Oral Cavity and Oropharynx
    Preț: 71260 lei
  • 5% Molecular Neuro-oncology and Its Impact on the Clinical Management of Brain Tumors
    Preț: 71152 lei
  • 5% Familial and Hereditary Tumors
    Preț: 71938 lei
  • 5% Hypercalcemia of Malignancy
    Preț: 70914 lei
  • 5% Soft Tissue Sarcomas in Adults
    Preț: 71006 lei
  • 5% Skin Cancer: Basic Science, Clinical Research and Treatment
    Preț: 72470 lei

Preț: 109848 lei

Preț vechi: 115629 lei
-5% Nou

Puncte Express: 1648
Preț estimativ în valută:
21025€ • 21667$ • 17750£

Carte tipărită la comandă

Livrare economică 03-17 martie

 Adaugă în coș

Wish list
Gift list
Am citit!
Adaugă în listă
Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9783642281594
ISBN-10: 3642281591
Pagini: 250
Ilustrații: XIV, 254 p.
Dimensiuni: 155 x 235 x 22 mm
Greutate: 0.52 kg
Ediția:2012
Editura: Springer Berlin, Heidelberg
Colecția Springer
Seria Recent Results in Cancer Research

Locul publicării:Berlin, Heidelberg, Germany

Public țintă

Professional/practitioner

Cuprins

Minimal residual disease and circulating tumor cells in breast cancer: Open questions for research.- Minimal residual disease and breast cancer metastasis.- Self-seeding in cancer.- Microenvironments dictating tumor cell dormancy.- Technologies for circulating tumor cell (CTC) and disseminated tumor cell (DTC) detection and characterization.- Immunomagnetic separation technologies.- Microfluidic technologies for the isolation of CTCs.- EPISPOT assay: Detection of viable disseminating tumor cells in solid tumor patients.- Advances in optical technologies for rare cell detection and characterization.- Size-based enrichment technologies for circulating tumor cell (CTC) detection and characterization.- Emerging technologies for CTC detection based on depletion of normal cells.- Molecular assays for the detection and characterization of CTCs.- Multiplex molecular analysis of CTCs.- Other blood-based biomarkers.- Circulating DNA and next generation sequencing.- Circulating microRNAs as non-invasive biomarkers in breast cancer.- Circulating endothelial cells and circulating endothelial progenitors.- Disseminated tumor cells (DTCs) and circulating tumor cells (CTCs) in breast cancer clinical research and practice.- Bone marrow DTCs.- CTCs in primary breast cancer.- CTCs in early breast cancer.- CTCs in metastatic breast cancer.- HER2-positive DTCs/CTCs in breast cancer.- DTCs and CTCs in breast cancer – 5 decades later.- Drug and circulating tumor cell co-development.- Challenges in drug and biomarker co-development.- Challenges and opportunities in the use of CTCs for companion diagnostic development.

Textul de pe ultima copertă

Most deaths from carcinomas are caused by the hematogenous dissemination of cancer cells to distant organs and the eventual development of metastases. When found in the bone marrow or peripheral blood of carcinoma patients, occult cancer cells are referred to as disseminated tumor cells (DTCs) or circulating tumor cells (CTCs). CTCs and DTCs are considered surrogates of minimal residual disease, i.e., the presence of malignant cells in distant organs that are undetectable by conventional imaging and laboratory tests used for tumor staging after curative surgery of the primary tumor.
 
In this book, leading investigators in the field provide up-to-date information on a series of important questions, including:
 
-  How can the study of minimal residual disease and CTCs help us to better understand breast cancer metastasis?
-  What technologies are available for the detection and characterization of CTCs and DTCs, and what are their relative merits?
-  How are DTCs and CTCs relevant to clinical research and practice?
- What is the role of other blood-based biomarkers such as circulating endothelial cells and circulating nucleic acids?
-  What are the challenges in drug and biomarker co-development and the use of CTCs for companion diagnostic development?
 
This book will be of interest and assistance to all who are engaged in the modern management of breast cancer.

Caracteristici

Provides up-to-date information on topical issues concerning minimal residual disease in breast cancer patients Appraises the technologies available for detection and characterization of circulating and disseminated tumor cells (CTCs/DTCs) Discusses the relevance of CTCs and DTCs in breast cancer clinical research and practice, and the role of other blood-based biomarkers Includes supplementary material: sn.pub/extras